Latest Breaking News On - Biktarvy through four years - Page 1 : comparemela.com

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI 98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – Gilead Sciences, Inc. today announced new, … >98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks –

United statesFoster cityJacquie rossBrian plummerKimberly workowskiDiana brainardExchange commissionGilead sciencesEmory universityGilead on twitter sciencesGilead public affairsGilead sciences incPatients achievedMaintained undetectable viral loadBiktarvy through four yearsOpen label extension phase